Centre for General Practice, Department of Family Medicine & Population Health (FAMPOP), University of Antwerp, Antwerp, Belgium.
Global Health Institute, Department of Family Medicine & Population Health (FAMPOP), University of Antwerp, Antwerp, Belgium.
BMC Infect Dis. 2024 Oct 10;24(1):1135. doi: 10.1186/s12879-024-09969-8.
COVID-19 vaccine effectiveness declines months after vaccination. Therefore, it is likely that during the next few years, people may be repeatedly offered a booster vaccine to enhance humoral immunity levels. A growing number of people are questioning whether the benefits of a booster vaccine outweigh the side-effects.
This study aims (1) to identify the most frequently reported side-effects after different doses of COVID-19 mRNA vaccines, (2) and the longest lasting symptoms; and (3) to predict the likelihood of having moderate-to-severe side-effects after a booster COVID-19 mRNA vaccine given individual- and vaccine-specific characteristics.
DESIGN, SETTING, AND PARTICIPANTS: Secondary analysis of a prospective cohort study in primary health care providers (PHCPs) in Belgium conducted between December 2020 and December 2021, and in February-March 2023.
In nine subsequent surveys over a period of 2 years vaccine dose-number and side-effects after COVID-19 vaccines were collected. A Generalized Estimation Equations approach on the data of the first and second booster dose was used to investigate the probability of having moderate-to-severe side-effects after mRNA booster vaccination. Predictive performance of a binary classifier was assessed by looking at discrimination (i.e., quantified in terms of the area under the receiver operating characteristic curve). The final prediction model was validated using data with regard to the third booster by assessing misclassification rate, sensitivity and specificity.
In total, 11% of the PHCPs had moderate-to-severe side-effects after their booster COVID-19 mRNA vaccine. The most common side-effects of COVID-19 mRNA doses included fatigue, local pain at the injection site, general pains, and headache. These side-effects typically lasted for a median of 1 to 2 days. The final model included five predictors: sex, alcohol consumption, history of moderate-to-severe side-effects after any previous dose, recent COVID-19 infection, and the booster dose-number (first, second). Having experienced moderate-to-severe side-effects after any previous dose was the strongest predictor of moderate-to-severe side-effects following an mRNA vaccine booster, with an odds ratio (OR) of 3.64 (95% CI: 2.80-4.75). The OR for female sex was 1.49 (95% CI: 1.21-1.84) implying that females have a higher odds of moderate-to-severe side-effects following booster vaccination. The differences in effect for booster dose-number, alcohol consumption and recent COVID-19 infection was not significant.
COVID-19 mRNA booster vaccination implies a low prevalence of moderate-to-severe side-effects among PHCPs, with a short median duration of symptoms if any. The strongest predictors are a history of moderate-to-severe side-effects after any previous dose and being female. These reassuring findings can help addressing concerns about booster vaccination and encourage their uptake.
NCT04779424 (registration date: 2021-02-22).
接种 COVID-19 疫苗几个月后,疫苗的有效性会下降。因此,在未来几年,人们可能会反复接种加强针,以提高体液免疫水平。越来越多的人开始质疑加强针疫苗的益处是否超过其副作用。
本研究旨在:(1)确定接种不同剂量的 COVID-19 mRNA 疫苗后最常报告的副作用;(2)以及最长持续时间的症状;(3)预测接种 COVID-19 mRNA 加强针后出现中重度副作用的可能性,根据个体和疫苗的特征。
设计、地点和参与者:这是一项在比利时基层医疗保健提供者(PHCPs)中进行的前瞻性队列研究的二次分析,该研究于 2020 年 12 月至 2021 年 12 月以及 2023 年 2 月至 3 月进行。
在为期 2 年的 9 次后续调查中,收集了 COVID-19 疫苗接种剂量和副作用的数据。使用广义估计方程方法对第一针和第二针加强针的数据进行分析,以研究 mRNA 加强针接种后出现中重度副作用的可能性。通过观察接受者操作特征曲线下的面积来评估二分类器的预测性能。使用第三针加强针的数据来验证最终预测模型,通过评估误分类率、敏感性和特异性来验证模型的准确性。
共有 11%的 PHCPs 在接种 COVID-19 mRNA 加强针后出现中重度副作用。COVID-19 mRNA 疫苗接种的最常见副作用包括疲劳、注射部位局部疼痛、全身疼痛和头痛。这些副作用通常持续 1 至 2 天。最终模型纳入了五个预测因素:性别、饮酒、以前任何剂量后出现中重度副作用的病史、近期 COVID-19 感染和加强针剂量数(第一针、第二针)。以前任何剂量后出现中重度副作用是接种 mRNA 加强针后出现中重度副作用的最强预测因素,比值比(OR)为 3.64(95%CI:2.80-4.75)。女性的 OR 为 1.49(95%CI:1.21-1.84),这意味着女性在接种加强针后出现中重度副作用的可能性更高。对于加强针剂量数、饮酒和近期 COVID-19 感染,其效应差异无统计学意义。
COVID-19 mRNA 加强针接种在 PHCPs 中引起中重度副作用的患病率较低,如果出现任何症状,其症状的中位数持续时间较短。最强的预测因素是以前任何剂量后出现中重度副作用的病史和女性。这些令人安心的发现可以帮助解决对加强针接种的担忧,并鼓励其接种。
NCT04779424(注册日期:2021-02-22)。